# Tamsulosin plus Tadalafil compared with Tamsulosin alone for benign prostate hyperplasia in patients with or without erectile dysfunction: a meta-analysis and meta-regression of randomized controlled trials

**Authors:** Tallal Mushtaq Hashmi, Rohma Zia, Hadiah Ashraf, Momina Siddiqui, Ali Haider, Valencia Rumampouw, Momina Aslam Khan, Mushood Ahmed, Javed Iqbal

PMC · DOI: 10.1007/s00345-025-05662-w · World Journal of Urology · 2025-05-11

## TL;DR

Combining tamsulosin and tadalafil improves symptoms and quality of life for prostate issues more than tamsulosin alone, but causes more side effects.

## Contribution

This study provides new evidence that combination therapy is more effective than monotherapy for benign prostate hyperplasia.

## Key findings

- Combination therapy reduces IPSS, improves IIEF, and enhances QoL more than tamsulosin alone.
- Combination therapy increases adverse events like pain compared to monotherapy.
- Meta-analysis shows significant improvement in Qmax and PVR with combination treatment.

## Abstract

Combination pharmacotherapy with tamsulosin plus tadalafil could be a superior strategy compared to conventional monotherapy with tamsulosin in patients with Benign prostatic obstruction (BPO) with or without erectile dysfunction.

A comprehensive search was conducted across PubMed, the Cochrane Library, and Embase to identify studies assessing the efficacy and safety of combination therapy compared with monotherapy in patients with BPO with or without erectile dysfunction. A random effects meta-analysis was performed with R version 4.4.1 using the 'meta' package.

We included eleven RCTs, with a combined total of 940 patients. Our analysis demonstrated that the combination therapy is associated with a greater reduction in overall IPSS (MD = − 2.78, 95% CI − 3.97 to − 1.59; P < 0.01), IIEF (MD = 2.98, 95% CI 1.64 to 4.33; P < 0.01), QoL score (MD = − 0.58, 95% CI − 0.86 to − 0.30; P < 0.01), PVR (MD = − 9.34, 95% CI = -15.52 to − 3.16; P < 0.01) and a significant improvement in Qmax (MD = 1.04, 95% CI 0.43 to 1.64; P < 0.01) as compared to tamsulosin alone. However, combination therapy resulted in a higher incidence of pain (OR = 5.66, 95% CI 2.56 to 12.52; P < 0.01) and other adverse events (OR = 2.97, 95% CI 1.60 to 5.49; P < 0.01).

Combination therapy with tamsulosin and tadalafil demonstrated superior efficacy over tamsulosin monotherapy in reducing LUTS, improving quality of life, and enhancing erectile function. However, it was associated with a higher incidence of adverse effects.

The online version contains supplementary material available at 10.1007/s00345-025-05662-w.

## Linked entities

- **Chemicals:** tamsulosin (PubChem CID 60147), tadalafil (PubChem CID 110635)
- **Diseases:** erectile dysfunction (MONDO:0005362)

## Full-text entities

- **Diseases:** pain (MESH:D010146), benign prostate hyperplasia (MESH:D011470), erectile dysfunction (MESH:D007172), BPO (MESH:D011472)
- **Chemicals:** Tamsulosin (MESH:D000077409), Tadalafil (MESH:D000068581)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12066372/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12066372/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC12066372/full.md

---
Source: https://tomesphere.com/paper/PMC12066372